AstraZeneca CCA virus (neo-coronavirus) vaccine is suspected of increasing the risk of blood clots. A new study found that people who received the Pfizer or Moderna vaccine had similar rates of similar blood clots as AstraZeneca recipients.
Researchers found that four out of one million patients developed symptoms of cerebral venous thrombosis (CVT) after administering the Pfizer or Moderna vaccines, compared with five of the AstraZeneca vaccine recipients.
The observational study was initiated by scientists from the University of Oxford. They used electronic health records to compare three groups of people. The subjects were either diagnosed with the CCA virus, diagnosed with the flu, or received the Pfizer or Moderna vaccine to see the incidence of rare blood clots they developed over a two-week period.
“Although Moderna and Pfizer vaccines with similar thrombotic risks are new findings, we cannot conclude that the mRNA vaccines studied here are associated with an increased risk of CVT. Additional samples are needed to address this question.” The researchers wrote. Both the Pfizer and Modena offerings are mRNA vaccines.
The study has not been peer-reviewed.
Since last month, some people from different countries have developed blood clotting problems after receiving the AstraZeneca vaccine. The vaccine is therefore under review by the EU drug regulator.
The European Medicines Agency (EMA) concluded in early April that there was a “possible link” between the vaccine and blood clots and recommended that AstraZeneca consider blood clots as a possible side effect of the vaccine.
This week, some recipients of the Johnson & Johnson vaccine developed blood clots after receiving the vaccine, triggering an almost nationwide suspension of the vaccine. U.S. health officials said the problems were similar to those seen in AstraZeneca vaccine recipients.
However, U.S. officials have also said that neither Modena nor Pfizer vaccines are associated with CVT, which is accompanied by low blood platelets in such cases.
“To be very clear, these types of reactions – thrombosis combined with low platelets – are not seen in the licensed vaccines from Pfizer and Modena.” Rochelle Walensky, director of the Centers for Disease Control and Prevention (CDC), said in an online briefing this week.
Moderna and Pfizer have also said that the evaluation of safety data did not show a link between their own vaccines and CVT or thrombotic events.
Blood clots a concern with both infection and vaccination, the former a higher risk
The new study is based on data recorded by TriNetX Analytics, a network of health records that provides information from the TriNetX network. This is a health records network that provides anonymized data from 59 medical facilities, most of which are in the United States.
The network has records for 81 million patients. Researchers looked at the records of 513,284 patients. Some of these patients were diagnosed with coronavirus (CCA virus) between Jan. 20 and March 25, 2020. A second group made their flu diagnosis during the same time frame, while a third group received either the Pfizer or Moderna vaccine for the CCP virus.
The results found that those infected with COVID-19 had an eight- to 10-fold higher risk of developing CVT within two weeks of making a diagnosis compared to those in the second and third groups.
“We draw two important conclusions. First, COVID-19 (a disease caused by the CCA virus) significantly increased the risk of CVT and increased the list of thrombosis triggered by this infection. Second, COVID-19 poses a higher risk than the vaccine (risk) currently seen, even for those under 30 years of age.” Paul Harrison, professor of psychiatry and head of the Translational Neurobiology Group at the University of Oxford, said in a statement.
“This should be taken into account when considering the risks and benefits of discretionary vaccination.” He suggested.
Recent Comments